Sign Up Today and Learn More About Congruence Therapeutics Stock
Invest in or calculate the value of your shares in Congruence Therapeutics or other pre-IPO companies through EquityZen's platform.
Congruence Therapeutics Stock (COTR)
Congruence Therapeutics operates as a biotechnology company.
About Congruence Therapeutics Stock
Founded
2021
Industries
Software, Artificial Intelligence, Data and Analytics
Congruence Therapeutics Press Mentions
Stay in the know about the latest news on Congruence Therapeutics
Congruence Therapeutics Earns "Fierce 15" Distinction for 2025
prnewswire • Sep 22, 2025
Congruence Therapeutics: $32 Million Financing Raised For Advancing Genetic Obesity Therapy
pulse2 • Sep 13, 2025
Congruence Therapeutics Announces Closing of $32M Financing to Advance First-in-Class Genetic Obesity Candidate Drug CGX-926 Through Phase 1b Proof of Concept Clinical Trial
prnewswire • Sep 05, 2025
Congruence Awarded Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to Advance Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations
prnewswire • Jul 24, 2025
Congruence Therapeutics Announces Oral Presentation on MC4R Corrector Development Candidate CGX-926 for Early-Onset Obesity at the 3rd Annual Obesity & Weight Loss Drug Development Summit
prnewswire • Jul 17, 2025
Join now and verify your accreditation status to gain access to:
- Congruence Therapeutics Current Valuation
- Congruence Therapeutics Stock Price
- Congruence Therapeutics Management
- Available deals in Congruence Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Congruence Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Congruence Therapeutics Revenue and Financials
- Congruence Therapeutics Highlights
- Congruence Therapeutics Business Model
- Congruence Therapeutics Risk Factors
- Congruence Therapeutics Research Report from SACRA Research
Trading Congruence Therapeutics Stock
How to invest in Congruence Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Congruence Therapeutics through EquityZen funds. These investments are made available by existing Congruence Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Congruence Therapeutics stock?
Shareholders can sell their Congruence Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 390K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 48K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
